Granulocyte transfusions: current status.
Since granulocyte transfusions first became widely used in clinical medicine, there have been advances in the treatment of acute leukemia and improvement in prevention and management of infection in neutropenic patients. Improved understanding now exists concerning prognosis of infections in such patients, and advances have been made in procurement of granulocytes. Granulocyte transfusions should be given for specific indications, and used adjunctively to other established antiinfective therapy. Once initiated, transfusions should be given in adequate doses at daily intervals (at least) with ongoing evaluation and periodic reassessment of the whole antiinfective program. Serious complications of granulocyte transfusion therapy are relatively rare, but the physician should be prepared to manage them intelligently. Research continues in discerning exactly how granulocyte transfusion work, in preservation of granulocytes, and in delineation of immunologic phenomena affecting the efficiacy of such therapy. Granulocyte transfusions will continue to be important in the management of acute leukemia, and other reversible bone marrow failure states, and in marrow transplantation and autotransplantation.
D000917:Antibody Formation; D001803:Blood Transfusion; D002448:Cell Adhesion; D002498:Centrifugation; D004903:Erythrocyte Aggregation; D005334:Fever / Q000209:etiology; D005374:Filtration; D006098:Granulocytes / Q000637:transplantation*; D006801:Humans; D007937:Leukapheresis; D009503:Neutropenia / Q000628:therapy; D011309:Preservation, Biological; D012306:Risk; D018805:Sepsis / Q000628:therapy